Bausch Health Companies Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings
Bausch Health Companies Inc. (BHC) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings of -$21.00 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-06.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 · last filed 2019-05-06
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2019-03-31 was -$21.00M, a 1150.00% decline year-over-year.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2018-12-31 was $14.00M, a 75.00% increase year-over-year.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2018-09-30 was -$19.00M.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2018-06-30 was -$6.00M.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2018 was -$9.00M.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2017 was -$289.00M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2019-03-31 | -$21.00M 10-Q · filed 2019-05-06 | -$7.00M derived: sum of 2 quarters · filed 2019-05-06 | -$26.00M derived: sum of 3 quarters · filed 2019-05-06 | -$32.00M derived: sum of 4 quarters · filed 2019-05-06 |
| 2018-12-31 | $14.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-20 | -$5.00M derived: sum of 2 quarters · filed 2019-02-20 | -$11.00M derived: sum of 3 quarters · filed 2019-02-20 | -$9.00M 10-K · filed 2019-02-20 |
| 2018-09-30 | -$19.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$25.00M derived: sum of 2 quarters · filed 2018-11-06 | -$23.00M 10-Q · filed 2018-11-06 | -$15.00M derived: sum of 4 quarters · filed 2019-05-06 |
| 2018-06-30 | -$6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | -$4.00M 10-Q · filed 2018-08-07 | $4.00M derived: sum of 3 quarters · filed 2019-05-06 | -$234.00M derived: sum of 4 quarters · filed 2019-05-06 |
| 2018-03-31 | $2.00M 10-Q · filed 2019-05-06 | $10.00M derived: sum of 2 quarters · filed 2019-05-06 | -$228.00M derived: sum of 3 quarters · filed 2019-05-06 | -$277.00M derived: sum of 4 quarters · filed 2019-05-06 |
| 2017-12-31 | $8.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-20 | -$230.00M derived: sum of 2 quarters · filed 2019-02-20 | -$279.00M derived: sum of 3 quarters · filed 2019-02-20 | -$289.00M 10-K · filed 2019-02-20 |
| 2017-09-30 | -$238.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$287.00M derived: sum of 2 quarters · filed 2018-11-06 | -$297.00M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | -$49.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$59.00M 10-Q · filed 2017-08-08 | ||
| 2017-03-31 | -$10.00M 10-Q · filed 2017-05-09 | |||
| 2016-12-31 | -$13.00M 8-K · filed 2018-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |